Verona Pharma plc's (NASDAQ:VRNA) Path To Profitability

By Yahoo! Finance | Aug 3, 2024 at 10:48 AM EST

Verona Pharma is a biopharmaceutical company focusing on respiratory diseases. Analysts predict breakeven by 2025, expecting a profit of US$60m in 2026 with a 59% growth rate. The company's low debt and strategic capital management reduce investment risks.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.